Cited 0 times in
Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정용은 | - |
dc.contributor.author | 최혜진 | - |
dc.contributor.author | 강창무 | - |
dc.contributor.author | 황호경 | - |
dc.contributor.author | 김현기 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 이우정 | - |
dc.date.accessioned | 2014-12-19T17:07:39Z | - |
dc.date.available | 2014-12-19T17:07:39Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1091-255X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90827 | - |
dc.description.abstract | BACKGROUND: Margin-negative pancreatectomy provides only chance to cure pancreatic cancer. However, borderline resectable pancreatic cancer (BRPCa) has the risk of incomplete palliative resection. MATERIALS AND METHODS: We retrospectively reviewed 32 patients with BRPCa who underwent a pancreatectomy following preoperative chemoradiation therapy (CCRT (+)/Px group) and compared these patients with those with resectable pancreatic cancer (RPCa) who underwent pancreatectomy without preoperative CCRT (CCRT (-)/Px group, n=104). RESULTS: Eighteen patients (56.2%) showed more than 50% significant pathological response to CCRT. The degree of pathological responses showed a positive relationship between final pT stage (p=0.075). More frequent vascular resection (p<0.001), transfusion (p=0.076), and longer operation time were observed in the CCRT(+)/Px group. However, similar R0 resection rates (p=0.272), lower pT stage (p<0.001), smaller number of metastastic lymph nodes (p=0.002), and lower incidence of lymph node metastasis (p=0.032) were noted in the CCRT(+)/Px group. The overall disease-specific survival were similar (median survival, 30.5 months (95% CI; 23.6-37.4) vs. 26.3 months (95% CI; 15.9-36.7), p=0.709), and no statistical differences in cancer recurrence risks were noted between the two groups (p=0.505). CONCLUSION: Pancreatectomy following preoperative neoadjuvant CCRT can be a potential strategy for margin-negative resection in BRPCa patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF GASTROINTESTINAL SURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/pathology* | - |
dc.subject.MESH | Adenocarcinoma/therapy | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Chemoradiotherapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoadjuvant Therapy | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Pancreatectomy* | - |
dc.subject.MESH | Pancreatic Neoplasms/pathology | - |
dc.subject.MESH | Pancreatic Neoplasms/therapy* | - |
dc.subject.MESH | Preoperative Care/methods* | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | Chang Moo Kang | - |
dc.contributor.googleauthor | Yong Eun Chung | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.contributor.googleauthor | Jin Sil Sung | - |
dc.contributor.googleauthor | Ho Kyoung Hwang | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Woo Jung Lee | - |
dc.identifier.doi | 22183861 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03662 | - |
dc.contributor.localId | A04219 | - |
dc.contributor.localId | A00088 | - |
dc.contributor.localId | A04497 | - |
dc.contributor.localId | A01108 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A02993 | - |
dc.relation.journalcode | J01418 | - |
dc.identifier.eissn | 1873-4626 | - |
dc.identifier.pmid | 22183861 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs11605-011-1784-3 | - |
dc.subject.keyword | Neoadjuvant | - |
dc.subject.keyword | Chemoradiation | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.subject.keyword | Borderline resectable | - |
dc.contributor.alternativeName | Chung, Yong Eun | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.alternativeName | Kang, Chang Moo | - |
dc.contributor.alternativeName | Hwang, Ho Kyoung | - |
dc.contributor.alternativeName | Kim, Hyun Ki | - |
dc.contributor.alternativeName | Park, Jeong Youp | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.affiliatedAuthor | Chung, Yong Eun | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Kang, Chang Moo | - |
dc.contributor.affiliatedAuthor | Hwang, Ho Kyoung | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Ki | - |
dc.contributor.affiliatedAuthor | Park, Jeong Youp | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.citation.volume | 16 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 509 | - |
dc.citation.endPage | 517 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROINTESTINAL SURGERY, Vol.16(3) : 509-517, 2012 | - |
dc.identifier.rimsid | 33559 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.